Held by 3 specialist biotech funds
High Convergence**Signal Note: RA Capital Initiates SLDB Position** RA Capital's $32.8M entry into Solid Biosciences signals conviction in SGT-001, the company's gene therapy for Duchenne muscular dystrophy (DMD), likely ahead of near-term clinical/regulatory catalysts.
AI analyst context — unlock full analysis
# Signal Note: Perceptive Advisors Initiates $66.7M Position in Solid Biosciences Edelman's new 11.8M share stake in SLDB signals confidence in the company's lead program SGT-001, an AAV gene therapy for Duchenne muscular dystrophy currently in Phase 2/3 development with near-term readouts expected. Perceptive's strong track record in clinical-stage biotech suggests conviction in SLDB's technical execution and commercial potential in the $1B+ DMD market, where limited treatment options create meaningful unmet need. Key catalysts include Phase 2/3 efficacy data and potential regulatory pathway clarity over the next 12-18 months.
+ 1 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial